SE446727B - Substituerade morfolinderivat och farmaceutisk komposition derav - Google Patents

Substituerade morfolinderivat och farmaceutisk komposition derav

Info

Publication number
SE446727B
SE446727B SE7900498A SE7900498A SE446727B SE 446727 B SE446727 B SE 446727B SE 7900498 A SE7900498 A SE 7900498A SE 7900498 A SE7900498 A SE 7900498A SE 446727 B SE446727 B SE 446727B
Authority
SE
Sweden
Prior art keywords
phenoxy
benzyl
morpholine
methoxy
ethoxy
Prior art date
Application number
SE7900498A
Other languages
English (en)
Swedish (sv)
Other versions
SE7900498L (sv
Inventor
P Melloni
Torre A Della
G C Carniel
A Rossi
Original Assignee
Erba Farmitalia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1944978A external-priority patent/IT1093255B/it
Priority claimed from IT1945078A external-priority patent/IT1111676B/it
Priority claimed from IT3053478A external-priority patent/IT1160302B/it
Priority claimed from IT30535/78A external-priority patent/IT1101724B/it
Priority claimed from IT3053378A external-priority patent/IT1160301B/it
Application filed by Erba Farmitalia filed Critical Erba Farmitalia
Publication of SE7900498L publication Critical patent/SE7900498L/xx
Publication of SE446727B publication Critical patent/SE446727B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/32—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C07D265/33—Two oxygen atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE7900498A 1978-01-20 1979-01-19 Substituerade morfolinderivat och farmaceutisk komposition derav SE446727B (sv)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT1944978A IT1093255B (it) 1978-01-20 1978-01-20 Derivati fenossialcanolaminici
IT1945078A IT1111676B (it) 1978-01-20 1978-01-20 Derivati della 2-fenossimetil-morfolina
IT3053478A IT1160302B (it) 1978-12-05 1978-12-05 Derivati della 2-fenossimentil-morfolina
IT30535/78A IT1101724B (it) 1978-12-05 1978-12-05 Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
IT3053378A IT1160301B (it) 1978-12-05 1978-12-05 Derivati fenossialcanolaminici

Publications (2)

Publication Number Publication Date
SE7900498L SE7900498L (sv) 1979-07-21
SE446727B true SE446727B (sv) 1986-10-06

Family

ID=27517788

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7900498A SE446727B (sv) 1978-01-20 1979-01-19 Substituerade morfolinderivat och farmaceutisk komposition derav

Country Status (24)

Country Link
US (2) US4229449A (de)
JP (1) JPS54148739A (de)
AT (1) AT371813B (de)
AU (1) AU525954B2 (de)
BG (1) BG61056B2 (de)
CA (1) CA1128942A (de)
CH (1) CH650245A5 (de)
CS (1) CS413391A3 (de)
CY (1) CY1172A (de)
DE (2) DE19875005I2 (de)
DK (1) DK156565C (de)
FI (1) FI71135C (de)
FR (2) FR2442839A1 (de)
GB (1) GB2014981B (de)
HK (1) HK5783A (de)
IE (1) IE47727B1 (de)
IL (1) IL56369A (de)
KE (1) KE3243A (de)
MY (1) MY8400018A (de)
NO (1) NO146953C (de)
NZ (1) NZ189418A (de)
SE (1) SE446727B (de)
SI (1) SI7910096A8 (de)
YU (1) YU42094B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226523A (en) * 1978-11-17 1980-10-07 Energy Conversion Devices, Inc. Imaging device
GB8419683D0 (en) * 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2162517B (en) * 1984-08-01 1988-04-27 Erba Farmitalia Process for the preparation of 3-substituted derivatives of 1-amino-2-hydroxy-propane
DE3546929B4 (de) * 1984-08-02 2006-02-09 Pharmacia Italia S.P.A. 1,2-substituierte Derivate von 3-Phenoxy-3-Phenylpropan
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
GB8823405D0 (en) * 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
JP2001517628A (ja) * 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU756373B2 (en) 1998-04-09 2003-01-09 Pharmacia & Upjohn Company New treatments for nervous disorders
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
SI1140788T1 (en) * 1998-12-29 2004-08-31 Pharmacia & Upjohn Company Method for the preparation of aryl ethers
EP1459749B1 (de) * 1999-07-01 2005-10-05 Pharmacia & Upjohn Company LLC (S,S)-Reboxetin zur Behandlung von Inkontinenz
AU2005220235B2 (en) * 1999-07-01 2007-05-10 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
ES2242175T3 (es) * 1999-07-01 2005-11-01 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar la fibromialgia y otros trastornos somatoformes.
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
AU2002213830A1 (en) * 2000-10-31 2002-05-15 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
EP1455770B1 (de) * 2001-11-30 2007-06-20 Eli Lilly And Company Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
EP1494664A2 (de) * 2002-04-18 2005-01-12 Pharmacia Corporation Kombinationen aus cox-2-hemmer und anderen agenten zur behandlung von morbus parkinsonian
WO2004016272A1 (en) * 2002-08-14 2004-02-26 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
EP1587782A1 (de) * 2002-11-05 2005-10-26 Eli Lilly and Company 3-aryloxy/thio-3-substituierte propanamine und deren verwendung zur inhibierung der wiederaufnahme von serotonin und norepinephrine
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
KR20060087560A (ko) * 2003-09-12 2006-08-02 워너-램버트 캄파니 엘엘씨 알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물
DE602004024317D1 (de) 2003-09-12 2010-01-07 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7402698B2 (en) * 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
WO2005082869A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
EP1730094A1 (de) * 2004-02-20 2006-12-13 Pharmacia & Upjohn Company LLC Verfahren zur herstellung von arylethern
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
US7368477B2 (en) * 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CA2614289A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (de) 2006-05-09 2009-02-25 Braincells, Inc. 5-ht-rezeptor-vermittelte neurogenese
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
EP2068872A1 (de) 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663984C (en) 2006-10-18 2012-02-21 Pfizer Products Inc. Biaryl ether urea compounds
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途
WO2010011811A2 (en) * 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US8247433B2 (en) 2008-11-14 2012-08-21 Theravance, Inc. Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
CN105254552A (zh) * 2009-07-13 2016-01-20 施万生物制药研发Ip有限责任公司 3-苯氧基甲基吡咯烷化合物
WO2011011231A1 (en) 2009-07-21 2011-01-27 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
US8778949B2 (en) 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
WO2012051103A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
BE759013R (fr) * 1969-11-17 1971-05-17 Ici Ltd Derives de la
GB1382526A (en) * 1972-08-11 1975-02-05 Ici Ltd Morpholine derivatives
GB1412546A (en) * 1973-08-08 1975-11-05 Ici Ltd Morpholine derivatives
GB1427097A (en) * 1973-10-18 1976-03-03 Ici Ltd Optically-active morpholine derivatives
GB1469410A (en) * 1973-12-17 1977-04-06 Christiaens Sa A Benzodioxole derivatives
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
CA1064927A (en) * 1975-01-29 1979-10-23 Yuji Kawashima Process of producing 2-(indenyloxymethyl) morpholine derivatives
GB1576216A (en) * 1975-01-29 1980-10-01 Yamanouchi Pharma Co Ltd 2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them
CA1085841A (en) * 1976-05-19 1980-09-16 Jean-Marie Ferland Aryloxy proplamines, their preparation and use thereof

Also Published As

Publication number Publication date
DK156565C (da) 1990-02-05
NO146953B (no) 1982-09-27
FR2442839A1 (fr) 1980-06-27
BG61056B2 (bg) 1996-09-30
FR2442839B1 (de) 1984-07-27
CH650245A5 (de) 1985-07-15
DE19875005I2 (de) 2002-10-24
JPS6331455B2 (de) 1988-06-23
FI71135B (fi) 1986-08-14
FI71135C (fi) 1986-11-24
FR2430412A1 (fr) 1980-02-01
IE790107L (en) 1979-07-20
AT371813B (de) 1983-08-10
IE47727B1 (en) 1984-05-30
NZ189418A (en) 1981-03-16
SI7910096A8 (sl) 1996-10-31
ATA40679A (de) 1982-12-15
FR2430412B1 (fr) 1987-06-26
JPS54148739A (en) 1979-11-21
YU42094B (en) 1988-04-30
DE2901032A1 (de) 1979-08-02
DK22679A (da) 1979-07-21
KE3243A (en) 1982-12-03
NO790205L (no) 1979-07-23
MY8400018A (en) 1984-12-31
AU4332779A (en) 1979-07-26
GB2014981B (en) 1982-08-11
CA1128942A (en) 1982-08-03
IL56369A (en) 1984-05-31
US4271160A (en) 1981-06-02
DK156565B (da) 1989-09-11
CS413391A3 (en) 1992-05-13
SE7900498L (sv) 1979-07-21
IL56369A0 (en) 1979-03-12
US4229449A (en) 1980-10-21
HK5783A (en) 1983-02-08
YU9679A (en) 1983-12-31
DE2901032C2 (de) 1996-05-30
NO146953C (no) 1983-01-05
GB2014981A (en) 1979-09-05
FI790177A (fi) 1979-07-21
CY1172A (en) 1983-06-10
AU525954B2 (en) 1982-12-09

Similar Documents

Publication Publication Date Title
SE446727B (sv) Substituerade morfolinderivat och farmaceutisk komposition derav
CA1341024C (en) Benzo-fused cycloalkane and oxa- and thia-, cycloalkane trans-1, 2-diamine derivatives
NO327535B1 (no) Produkter av amidinderivater samt anvendelse derav og medikament og farmasoytisk preparat
NO147950B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminoalkyl-heterocykliske forbindelser
NO170973B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyridinetanolaminderivater
DK147068B (da) Analogifremgangsmaade til fremstilling af 1-naphthylmethyl-cinnamyl-aminderivater
ITMI20010042A1 (it) Composti di eteri e di ammidi e loro preparazione come antidiabetici
NO178263B (no) Nye benzomorfaner og deres anvendelse som legemiddel
WO2008081477A1 (en) 3-aryloxy 3-substituted propanamines
JPH04210944A (ja) アミノアルコキシ芳香族化合物
NZ502128A (en) Benzothiophene compounds and their use in treating neurological disorders
US20100210663A1 (en) Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity
AU629258B2 (en) Aryloxy-, arylthio-, heteroaryloxy-, heteroarylthio- alkenylene derivatives of amines
NZ227565A (en) Pyrazol- and indazol- pyridine amines and pharmaceutical compositions
US3965181A (en) Tricyclic pharmacological agents, intermediates and methods of making
DK153547B (da) Analogifremgangsmaade til fremstilling af aminoalkoxypyrazoler eller salte deraf
Yous et al. Synthesis of the Naphthalenic Bioisostere of Indorenate. Synthese des Naphthalin‐Bioisosters von Indorenat
Perrone et al. Monophenolic 2-amino-1-indanone and 2-amino-1-tetralone derivatives: synthesis and assessment of dopaminergic activity
US3951987A (en) Tetrahydropyridine derivatives
US4772719A (en) Process for the preparation of 3,5-disubstituted isoxazoles
BE873596A (fr) Propanolamines et morpholines substituees et procede de preparation.
NO174098B (no) Analogifremgangsmaate for fremstilling av aryloksy- og heteroaryloksyalkenylenderivater av aminer
SK286076B6 (sk) Inhibítory biosyntézy cholesterolu a ergosterolu,spôsob ich prípravy a použitie
Zhao et al. A PRACTICAL SYNTHESIS OF 4-ACETYL-2, 3, 4, 5-TETRAHYDRO-1 H-1, 4-BENZODIAZEPINE
NZ616676A (en) Benzo [b] [1,4] oxazin derivatives as calcium sensing receptor modulators

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7900498-2

Format of ref document f/p: F

SPCF Application for supplementary protection certificate filed

Free format text: 9890011, 971030

NUG Patent has lapsed

Ref document number: 7900498-2

Format of ref document f/p: F

SPCG Supplementary protection certificate granted

Free format text: 9890011, 971030, EXPIRES: 20040119